

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

**1. (currently amended)** A water-in-oil W/O microemulsion comprising a retinoid and a phospholipid emulsifier as active ingredient, and sodium hyaluronate,

wherein:

the aqueous phase is present at a concentration ranging from 0.5 to 2% by weight;

the phospholipid emulsifier is phosphatidylcholine or soy lecithin, and is present in an amount ranging from 10 to 15% by weight;

the sodium hyaluronate is a fraction having a molecular weight ranging from 50 to 200 kDa, and is present in an amount ranging from 0.001 to 0.01% by weight; and

the ratio of molar water concentration to molar lecithin concentration (W/lec) is 3.

**2. (cancelled)**

**3. (previously presented)** The microemulsion of claim 1, wherein the oily phase consists of alkyl esters fatty acids.

**4. (previously presented)** The microemulsion of claim 3, wherein the oily phase consists of isopropyl palmitate.

**5. (previously presented)** The microemulsion of claim 1, wherein the retinoid is selected from the group consisting of isotretinoin (13-cis-retinoic acid), tazarotene and fenretinide.

**6. (previously presented)** The microemulsion of claim 5, wherein the retinoid is fenretinide.

**7. (canceled)**

**8. (previously presented)** The microemulsion of claim 1, further comprising at least one derivative of hyaluronic acid (HA) selected from the group consisting of:

HA salts with organic inorganic bases with a molecular weight of 50-730 KDa or a high molecular weight of 750-1230 KDa;

esters of HA with alcohols of the aliphatic, araliphatic, cycloaliphatic, aromatic, cyclic and heterocyclic series;

amides of HA with amines of the aliphatic, araliphatic, cycloaliphatic, aromatic, cyclic and heterocyclic series;

HA derivatives up to the 4th degree of sulphation; and  
inner esters of HA.

**9. (previously presented)** The microemulsion of claim 1, further comprising antioxidants and preservatives.

**10. (previously presented)** The microemulsion of claim 9, containing a-tocopherol and parabens.

**11. (previously presented)** A pharmaceutical composition comprising the microemulsions of claim 1.

**12. (previously presented)** A method of preparing medicinal products with chemoprotective activity, which comprises adding an effective amount of the microemulsion according to claim 1 to an acceptable carrier.

**13. (previously presented)** A method for preparing the microemulsion of claim 1, which comprises the addition of a solution of phospholipid emulsifier in the oily phase to a retinoid solution in the same oily phase, or the subsequent addition of an aqueous solution, possibly containing hyaluronic acid, salts or derivatives thereof, preservatives, EDTA and other components.

**14. (currently amended)** The microemulsion of claim 1, wherein the weight percentage of active ingredients is from 0.01%

to 0.5% in weight ~~and the weight percentage of sodium hyaluronate is from 0.001 to 0.01% in weight.~~

**15. (currently amended)** The microemulsion of claim 1, wherein the ~~use of~~ sodium hyaluronate promotes percutaneous absorption of the water-in-oil microemulsion.

**16. (new)** The microemulsion of claim 1, wherein the fraction of sodium hyaluronate having a molecular weight ranging from 50 to 200 kDa is hyalastine.